MK
Therapeutic Areas
Mineralys Therapeutics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Lorundrostat (MLS-101) | Uncontrolled Hypertension | Phase 2 |
| Next-generation aldosterone synthase inhibitors | Hypertension | Preclinical |
Leadership Team at Mineralys Therapeutics
JC
Jon Congleton
Chief Executive Officer
AL
Adam Levy
Chief Medical Officer
BJ
Brian J. Dziewior
Chief Financial Officer
DR
David Rodman
Chief Development Officer
BJ
Brian J. Dziewior
Director
DR
David Rodman
Director
BJ
Brian J.G. Pereira
Chairman of the Board
EW
Elise Wang
Director
CY
Christopher Y. Chai
Director
RW
Roderick Wong
Director